VACCINE INGREDIENTS

(Pneumoccal 7-valent vaccine, Diphtheria Protein)

Prevnar, vaccine package insert summary, Wyeth Pharmaceuticals. Inc., Philadelphia, PA, January 2004

Ingredients:

-Streptococcus pneumoniae stereotypes 4, 6B, 9V, 14, 18C, 19F, 23F

joined to diphtheria CRM protein isolated from cultures of Coynebacterium diphtheria strain C7 (B197);

-aluminum phosphate;

-ammonium sulfate

-casamioacids;

-soy peptone broth

-yeast;

Contraindications

-hypersensitivity reaction to ingredients including diptherua weakened toxin;

-delay for severe or moderate fever;

Warnings

-no protection from diseases caused by serotypes unrelated to those vaccine;

-package contains dry natural rubber;

-Sudden Infant Death Syndrome (SIDS) mentioned in specific studies;

Precautions

-fever and seizure reported after vaccination;

-acetaminophen may be given to reduce possibility of post-vaccination fever;

-given with caution for children on anti-coagulant therapy;

-unknown clinical relevance for inconsistent differences in response to pertussis atingens;

-unavailable immune data for MMR and chickenpox vaccine with Prevnars

-no evaluation for carciogeicity, mutageicity or fertility impairment;

-no animal reproduction studies;

-unknown if vaccine can cause fetal harm when injected into a pregnant woman or can affect reproduction capacity;

-not recommended for pregnant women;

-unknown whether vaccine is excreted in breast milk;

-not recommended for nursing mothers;

-safety and effectiveness not established for children below 6 weeks or over 10 years;

-no immune response studies on premature infants;

-not recommended for adults;

Adverse Reactions: apnea, appetite-decrease, breath-shortness, brocospasm, diarrhea, drowsiness, edema, face edema, fever, injection site: hives, itching, lymph system, redness, irritability, seizure, shock, sleep-restless, vomiting. More adverse reactions are listed.

In a Kaiser Permanente study of 17, 066 subjects, from October 1995 to April 1998, within 3 days of a dose, there were 24 hospitalizations for 29 diagnoses, 162 emergency room visits for 182 diagnoses.

Lederle Laboratories, Data on File, D118-P8: 12 references;

For complete information, ask your doctor for Prevnar vaccine package insert.

Poliovirus Vaccine Inactivated

IPOL vaccine package insert summary, Aventis Pasteur SA, Lyon, France, 1999.

Ingredients

Type 1 (Mahoney), Type 2 (MEF-1), Type 3 (Saukett) grown in VERO monkey kidney cells, grown in Eagle MEM

-newborn calf serum;

-M-199 medium replaces culture medium;

-formaldehyde;

-neomycin;

-polymyxin;

-streptomycin;

-2-phenoxyethanol

Contraindications

-history of sensitivity to any ingredient;

-if shock occurs within 24 hours of one dose;

-acute fever;

Warnings

-syringe needle cover contains dry, latex rubber;

-systemic adverse reactions reported in infants receiving inactivated polio vaccine (IPV) at same time at separate sites or combined with diphtheria-pertussis-tetanus (DPT) similar to those associated with DPT alone;

-deaths reported after IPV injections;

Precautions

-no long-term studies to evaluate carcinogenicity, mutagenicity or fertility impairment;

-no animal reproduction studies;

-unknown if IPOL can cause fetal harm when injected into a pregnant woman or can effect reproduction capacity;

-unknown if IPOL is excreted in breast milk;

Adverse Reactions: anorexia, fever, injection site hardness, pain, redness, swelling, tenderness, fussiness, irritability, persistent crying, sleepiness, tiredness, vomiting;

3 references to unpublished data available from Aventis Pasteur SA

For complete information, ask your doctor for IPOL’s vaccine package insert.

Haemophilus b & Meningococcal Protein vaccine

Liquid PedvaxHIB, vaccine package insert summary, Merck & Co., Inc. West Point, PA, 1998

Ingredients

-Haemophilus influenza B Ross strain bound to B11 Neisseria

meningitides serogroup B, purified by ethanol fractionation, enzyme digestion, phenol extraction, diafiltration, detergent extraction, sterile filtration;

-aluminum hydroxide;

-sodium chloride;

Contraindications

-hypersensitivity reaction to ingredients;

Precautions

-HIB disease may occur in week after vaccination;

-Liquid PedvaxHIB not evaluated for carcinogenicity, mutagenicity or fertility impairment;

-no animal reproduction studies;

-sensitive tests may detect vaccine components in urine for at least 30 days;

-safety and effectiveness not established in infants below 2 months or older than 6 years;

-vaccination delayed for moderate, severe or acute fevers;

-epinephrine available for possible allergic reaction;

Adverse Reactions: crying (unusual, high-pitched and or prolonged), diarrhea, drowsiness, ear pain, fever, fussiness, injection site abscess, pain, soreness, swelling, irritability, rash, seizures, sleepiness, upper respiratory infection, vomiting. More adverse reactions are listed.

Data on File at Merck Research Laboratories: 4 references

For complete information, ask your doctor for Liquid PedvaxHIB vaccine package insert.

Measles, Mumps and Rubella (German measles) Live virus Vaccine

M-M-R II, vaccine package insert summary, Merck & Co., Whitehouse Station, NJ October 2003

Ingredients

-Attenuvax: live measles virus from Eders’ weakened Edmonston strain grown in chick embryo cell culture;

-Mumpsvax: Jerry Lynn (B level) strain of live mumps virus grown in chick embryo cell culture;

-Meruvax:Wistar RA 27/3 strain of live weakened rubella virus grown in WI-38 aborted human lung fibroblasts (connective tissue cells);

-fetal bovine serum;

-hydrolyzed gelatin;

-glutamate;

-human albumin (processed using Cohn cold ethanol fractionation,

-medium 199

-Minimum Essential Medium;

-neomycin;

-sodium chloride;

-sodium phosphate;

-sorbitol;

-sucrose;

Contraindications

-hypersensitivity reaction to ingredients including gelatin;

-no vaccination for pregnant women; unknown vaccine effects on fetus;

-pregnancy avoided for 3 months after vaccination;

-respiratory fever; active fever infection

Warnings

-elevated fever may occur after vaccination;

-remote risk of viral disease from albumin, derivative of human blood;

-theoretical risk of Creutzfeldt-Jacob disease (CJD);

-hypersensitivity to ingredients including eggs, neomycin;

-people with thrombocytopenis (low platelets resulting in bleeding and easy bruising);

Precautions

-epinephrine available for possible allergic reaction;

-transmission of rubella virus through breast milk;

-unknown if measles or mumps virus excreted in breast milk;

-deferred vaccination (3 months or longer) after transfusions or human immune globulin;

-live rubella virus excretion from nose or throat of susceptible people 7-28 days after vaccination, transmission through close contact , accepted as theoretical risk, not regarded as a significant risk;

-reports of individual measles, mumps, rubella vaccines may result in temporary depression of tuberculin skin sensitivity;

-no studies on effect of measles vaccine on untreated tuberculosis children;

-no vaccination for people with active, untreated tuberculosis;

-no evaluation for carcinogenicity, mutagenicity or fertility impairment;

-no animal reproduction studies;

-unknown if vaccine can cause fetal harm when injected into a pregnant woman or can affect reproduction capacity;

-pregnancy avoided for 3 months after vaccination;

-safety and effectiveness to established for measles vaccine in infants under 6 months;

-safety ad effectiveness not established for mumps and rubella vaccine in infants less than 12 months;

-M-M-R II given one month before or after other live virus vaccines;

-limited data, thus not recommended, for simultaneous vaccination with diphtheria/pertussis/tetanus (DPT) and or oral polio vaccine (OPV);

Adverse Reactions: arthritis, atypical measles, brain disease, convulsions, cough, death (reported rarely, no established causal link), diabetes, diarrhea, dizziness, ear, (middle infection) and nerve deafness, edema, eye paralysis, fainting, fever, Guillain-Barre Syndrome, headache, injection site-burning, redness, stinging, swelling, tenderness, tissue hardening, irritability, itchiness, hives, meningitis (aseptic), sclerosis (brain), nausea, nerve inflammation, nose inflammation, pitting of abdomen & thigh, pneumonia, rash, seizures, sore throat, testes inflammation, upper respiratory infection, visual disturbances, vomiting, weakness. More adverse reactions are listed.

Data on file at Merck Research Laboratories;

For complete information, ask your doctor for M-M-R II vaccine package insert.

Hepatitis B Vaccine-genetically-engineered

Recombivax HB, vaccine package insert summary, Merck & Co., Inc., Whitehouse Station, NJ August 2002

Ingredients

-viral vaccine derived from hepatitis B surface antigen (HBsAG)

cloned into genetically-engineered strain of yeast Saccharomyces

cervisiae on a fermented medium;

-aluminum hydroxide;

-amino acids;

-dextrose;

-formaldehyde;

-mineral salts;

-phosphate buffer;

-potassium aluminum sulfate (alum);

-soy peptone;

-thimerosal (49.6 percent ethyl mercury);

-yeast;

Formulations: Pediatric/Adolescent (with and without preservative thimerosal);

Adult (with and without preservative thimerosal);

Dialysis (with and without preservative thimerosal);

Contraindications

-hypersensitivity reaction to ingredients including yeast;

Warnings

-no further injections if hypersensitivity symptoms occur;

-vaccine may not prevent hepatitis B in people with an unrecognized infection;

-after penetration and use, single dose vial, without thimerosal, has to be discarded;

Precautions

-epinephrine available for possible allergic reaction;

-no vaccination if present serious active infection or fever;

-no evaluation for carcinogenicity, mutagenicity or fertility impairment;

-no animal reproduction studies;

-unknown if vaccine can cause fetal harm when injected into a pregnant woman or can affect reproduction capacity;

-unknown of vaccine excreted in breast milk;

-safety and effectiveness of dialysis formulation not established in children;

-unknown protective duration effect in healthy vaccines;

-no defined need for booster doses;

Adverse Reactions: agitation, arthritis, Bell’s Palsy, brain disease, diarrhea, drowsiness, ear ringing, edema, fainting, fatigue, fever, flu, Guillain-Barre Syndrome, headache, injection site bruise, itchiness, nodule, pain, redness, soreness, swelling, tenderness, warmth, irritability, hair loss, hives, liver enzymes elevation, lupus-like syndrome, migraine, multiple sclerosis, nausea, rash, sore throat, spinal cord inflammation, upper respiratory infection, visual disturbances, weakness. More adverse reactions are listed.

Data on File at Merck Research Laboratories: 2 references;

For complete information ask your doctor for Recombivax HB vaccine package insert.

Influenza Virus Vaccine

Fluzone vaccine package insert summary, Aventis Pasteur, Swiftwater, PA, July 2005

Ingredients

-influenza viruses propagated in chicken embryo eggs:

A/New Caledonia/20/99/IVR-116 (H1N1);

A/New York/55/2004/X-157 (H3N2) (an A/California/7/2004-like strain);

B/Jiangsu/10/2003 (a B/Shanghai/361/2002-like strain;

-formaldehyde;

-gelatin;

-hemagglutinin;

-sucrose;

-octoxinol-9 (Triton X-100);

-sodium phosphate-buffered isotonic sodium chloride solution;

-thimerosal (49.6 percent mercury);

(4 presentations: 5ml vial with thimerosal, .25ml prefilled syringe (pink syringe plunger rod) without thimerosal, .5ml prefilled syringe for 36 months and older without thimerosal for 6-35 months of age; 5ml vial without thimerosal for 36 months age and older;

Contraindications

-hypersensitivity reaction to ingredients including eggs, egg products, chicken;

-postponed vaccination due to fever or acute disease;

The Advisory Committee for Immunization Practices (ACIP) recommended vaccine for women who wwill be pregnant during flu season No data or evidence exists of any harm caused by the level of the exposure that might occur from flu vaccination. The benefit of flu vaccination with thimerosal outweighs potential risk for thimerosal

Warnings

-not given to people with Guillain-Barre Syndrome history;

-coincidental, respiratory disease unrelated to flu vaccine can occur after vaccination;

Precautions

-epinephrine available for possible allergic reaction;

-protection from flu viruses limited to prepared or closely-related strains

-no animal reproduction studies;

-unknown if vaccine can cause fetal harm when injected into a pregnant woman or can affect reproduction capacity;

-unclear evidence linking Guillain-Barre Syndrome with flu vaccines;

-no recapping of needles and disposed of according to biohazard waste guidelines;

Adverse Reactions: brain disease, ear pain, facial paralysis (partial), fever, injection site pain, soreness, swelling, muscle pain, nerves affecting arms, hands, shoulders, weakness. More adverse reactions are listed.

Adventis Pasteur Inc., Data on File, MKT5720: 4 references;

For complete information, ask your doctor for Fluzone vaccine package insert.

Diphtheria , Tetanus, acellular Pertussis vaccine (DTaP)

Infanrix vaccine package insert summary, GlaxoSmithKline (Manufacturing by Chiron Behring GmbH & Co, Marburg, Germany and GlaxoSmithKline Biologicals, Rixensart, Belgium.) August 2003

Ingredients

-Diphtheria toxin:Coynebacterium diphtheriae in Fenton medium containing a bovine extract;

-Tetanus toxin: Clostridium tetani in Lathum medium from bovine casein;

-3 acellular pertussis antigens (PT, FHA, pertactin): Bordetella pertussis culture in modified Stainer-Scholte liquid medium;

-aluminum hydroxide;

-formaldehyde;

-glutaraldehyde;

-2-phenoxyethanol,

-polysorbate 80 (Tween 80).

Contraindications

-coma, decreased level of consciousness, prolonged seizures within 7 days of previous dose of pertussis-containing vaccine not attributable to identifiable cause;

-severe allergic or hypersensitivity reaction to ingredients;

Warnings

-previous adverse reactions from whole cell diphtheria-pertussis-tetanus (DPT) or acellular pertussis vaccines: 105’ F

-temperature within 48 hours not due to identifiable cause

-collapse within 48 hours, more than 3 hours of persistent, inconsolable crying within 48 hours

-seizures with or without fever within 3 days;

-Guillain-Barre syndrome within 6 weeks of prior dose of tetanus-containing vaccine;

-dry latex rubber in tip cap and rubber plunger of needless prefilled syringes;

-vaccination deferred during moderate or severe illness with and without fever;

-Sudden Infant Death Syndrome (SIDS) mentioned in specific studies;

Precautions

-Infanrix not evaluated for carcinogenicity, mutagenicity or fertility impairment

-no animal reproduction studies;

-unknown if Infanrix can cause fetal harm when injected into a pregnant woman or if Infanrix can affect reproduction capacity.

Adverse Reactions: appetite loss, crying, diarrhea, drowsiness, fever, fussiness, irritability, pain, rash, seizures, site redness & swelling, Sudden Infant Death Syndrome (SIDS), vomiting. Twenty or more worldwide reports are listed for above reactions. More adverse reactions are listed.

Data on File at GlaxoSmithKline: 9 references;

For complete information, ask your doctor for Infanrix vaccine package insert.

Diphtheria, Tetanus, acellular Pertussis (DTaP), Diphtheria, Tetanus, acellular Pertussis (DTaP), genetically-engineered Hepatitis B, Poliovirus (IPV) vaccine

Summary: Pediarix vaccine package insert summary, GlaxoSmithKline (Manufacturing by Chiron Behring GmbH & Co, Marburg, Germany and GlaxoSmithKline Biologicals, Rixensart, Belgium.) August 2003

Ingredients

-diphtheria toxin: Coynebacterium diphtheriae in Fenton medium containing a bovine extract;

-tetanus toxin: Clostridium tetani in Lathum medium from bovine casein;

-3 acellular pertussis antigens (PT, FHA, pertactin): Bordetella pertussis culture in modified Stainer-Scholte liquid medium;

-hepatitis B: cultured genetically-engineered Saccharomyces cerevisiae cells;

-poliovirus: 3 strains grow in monkey kidney cells (Vero) cultivated on microcarriers;

-aluminum hydroxide

-aluminum phosphate;

-calf serum;

-cysteine to remove residual thimerosal;

-formaldehyde;

-glutaraldehyde;

-lactalbumin hydrolysate

-neomycin sulfate

-2-phenoxyethanol

-polymixin B;

-polysorbate 80 (Tween 80);

-sodium chloride;

-thimerosal (49.6% mercury/12.5 ng mercury per dose);

-yeast.

Contraindications

-coma, decreased level of consciousness, prolonged seizures within 7 days of previous dose of pertussis-containing vaccine not attributable to identifiable cause.

-severe allergic or hypersensitivity reaction to ingredients;

Warnings

-previous adverse reactions from whole cell diphtheria-pertussis-tetanus (DPT) or acellular pertussis vaccines: 105 F

-temperature within 48 hours not due to identifiable cause

-collapse within 48 hours, persistent, more than 3 hours of inconsolable crying within 48 hours;

- seizures with or without fever within 3 days;

-Guillain-Barre syndrome within 6 weeks of prior dose of tetanus-containing vaccine;

-dry latex rubber in tip cap and rubber plunger of needleless prefilled syringes;

-vaccination deferred during moderate or severe illness with and without fever;

-Sudden Infant Death Syndrome (SIDS) mentioned in specific studies;

Precautions

-Infanrix not evaluated for carcinogenicity, mutagenicity or fertility impairment;

-no animal reproduction studies; -

-unknown if Infanrix can cause fetal harm when given to a pregnant woman or if Infanrix can affect reproduction capacity

-no safety and effectiveness of Infantrix studied and/or evaluated in children previously vaccinated with one or more doses of: hepatitis B vaccine, Infanrix, IPV, and interchangeablity of Pediarix and licensed DTaP, IPV and genetically-engineered hepatitis B vaccine;

-Pediarix given with caution for children with bleeding disorders;

-epinephrine available for allergic reactions;

Adverse Reactions: anorexia, appetite loss, crying, diarrhea, drowsiness, ear pain, fever, fussiness, irritability, liver function tests abnormal, pain, rash, seizures, site redness & swelling, Sudden Infant Death Syndrome (SIDS), vomiting. Twenty or more worldwide reports are listed for above reactions. More adverse reactions are listed.

For complete information, ask your doctor for Pediarix vaccine package insert.

MENINGOCOCCAL POLYSACCHARIDE VACCINE Groups A, C, Y and W-135 combined

Menomune-A/C/Y/W-135, Connaught Laboratories, Inc., Swiftwater, Pa. June 1998

Ingredients

• organisms/toxins from Neisseria meningitidis Group A, C, Y and W-135 cultivated with Mueller Hinton agar and Watson Scherp media;

• lactose;
• sodium chloride;
• thimerosal (49.6% ethyl mercury);
• toxin-free distilled water.

Facts

• clinical protection not documented;

• no protection against infections caused by organism other than Groups A, C, Y and W-135 meningococci;
• no protection against other disease agents, including N.meningitidis serogroupB, that may cause meningitis;
• vaccine may not protect 100% of susceptible persons;
• vaccine’s safety and effectiveness not established in children under 2-years-old

Contraindications

• injection contraindicated into persons known to be sensitive to thimerosal or other vaccine ingredients;

• vaccination deferred during acute illness;
• vaccine not indicated for infants and children under 2-years-old except as short-term protection of infants 3 months and older against Group A.

Warnings

• vial stopper contains dry natural latex rubber;

• vaccine not given at same time as whole cell-cell pertussis or whole-cell typhoid vaccines due to combined endotoxin content.

Precautions

• epinephrine injection available to combat shock or other allergic reactions;

• no evaluation in animals for cancer, gene change potentials or fertility impairment;
• no animal reproduction studies;
• unknown if vaccine can cause fetal harm when injected into a pregnant woman or can affect reproduction capacity;
• on limited data, no evidence of fetus abnormality in studies of vaccines injected into pregnant women;
• patients, parents, guardians need all information on vaccine’s risks and benefits;
• date, lot number, vaccine manufacturer need to be recorded by doctor.

Adverse Reactions

• chills;

• fever
• headaches;
• injection site: pain, redness, swelling, tenderness, tissue hardening
• kidney disease;
• weakness;
  

Unpublished data available at Connaught Laboratories, Inc.

For complete information, ask your doctor for Menomune’s vaccine package insert

IVAC CONCERNS
Vaccine side effects range from infant high-pitched screaming, seizures and severe joint pains to chronic fatigue, behavioral problems and death which public health bureaucrats label coincidental. Researchers link vaccines and autism, which in Illinois has increased 816 percent from 1992-1999.

It is imperative that doctors provide readable vaccine package inserts to their patients. According to court precedent, if a vaccine damages you or your child in a way described in the package inserts, the manufacturer is free of liability.

Based on federal recommendations an Illinois 18-month-old-child could receive 22 shots of 12 vaccine in 32 doses.

IVAC is troubled by The Jordan Report 2000 listing 367 new vaccines plus 162 AIDS vaccines added to 97 marketed vaccines. Possible future vaccines include those in foods, nasal sprays, shampoos and patches.

IVAC questions the safety and necessary of the following vaccine ingredients:

• Aluminum
• Calf serum
• Fetal bovine serum
• Formaldehyde
• Hydrolyzed gelatin
• Lactose
• Monosodium glutamate (MSG)
• Neomycin
• Phenol
• Streptomycin
• Sucrose
• Thimerosal (49.9% mercury)
• Yeast
• MRC-5 cells: DNA and protein
  (aborted fetal tissue cells)
  

R. Gordon Douglas, Jr., M.D., president of the vaccine division of Merck told IVAC that MSG is in all the viral vaccines because without it the viruses would die. He thought MSG was in all bacterial vaccines. When asked why MSG was only listed in Merck's chickenpox vaccine, he said MSG is in the other vaccines' culture mediums and manufacturers don't have to list the ingredients. MSG causes brain damage in laboratory animals.

IVAC is concerned with the cross-species in the culture mediums, i.e., chicken embryos, guinea pig cells, monkey kidney cells. SV40, implicated in many cancers, was in the polio vaccines from 1955-1962.

IVAC is outraged that any vaccine is given to babies less than 12 hours old, with or without the parents' consent. It is scandalous that the Illinois Department of Children and Family Services' (DCFS) employees have threatened parents with medical neglect for choosing to have their children vaccine-free.

NOTE: Illinois allows medical and religious belief exemptions for mandatory vaccinations.